- •Patients with post-PV MF demonstrated a higher incidence of thrombosis, especially venous thrombosis.
- •JAK2V617F allele burden ≥75% associated with venous thrombosis in post-PV MF.
- •≥1 DTA gene mutation in post-PV MF may increase the risk for thrombosis, especially the ASXL1 mutation.
- •Palpable splenomegaly was a risk factor for thrombosis in post-PV MF.
- •According to risk factor for thrombosis, a prognostic model was developed in post-PV MF.
Purchase one-time access:Academic & Personal: 24 hour online accessCorporate R&D Professionals: 24 hour online access
One-time access price info
- For academic or personal research use, select 'Academic and Personal'
- For corporate R&D use, select 'Corporate R&D Professionals'
- Philadelphia-negative classical myeloproliferative neoplasms: critical concepts and management recommendations from european LeukemiaNet.J. Clin. Oncol. 2011; 29: 761-770https://doi.org/10.1200/jco.2010.31.8436
- The 2016 WHO classification and diagnostic criteria for myeloproliferative neoplasms: document summary and in-depth discussion.Blood Cancer J. 2018; 8: 15https://doi.org/10.1038/s41408-018-0054-y
- Incidence and risk factors for myelofibrotic transformation among 272 Chinese patients with JAK2-mutated polycythemia vera.Am. J. Hematol. 2015; 90: 1116-1121https://doi.org/10.1002/ajh.24191
- Risk factors for arterial versus venous thrombosis in polycythemia vera: a single center experience in 587 patients.Blood Cancer J. 2017; 7: 662https://doi.org/10.1038/s41408-017-0035-6
- Survival and prognosis among 1545 patients with contemporary polycythemia vera: an international study.Leukemia. 2013; 27: 1874-1881https://doi.org/10.1038/leu.2013.163
- Vascular and neoplastic risk in a large cohort of patients with polycythemia vera.J. Clin. Oncol. 2005; 23: 2224-2232https://doi.org/10.1200/jco.2005.07.062
- Primary myelofibrosis (PMF), post polycythemia vera myelofibrosis (post-PV MF), post essential thrombocythemia myelofibrosis (post-ET MF), blast phase PMF (PMF-BP): consensus on terminology by the international working group for myelofibrosis research and treatment (IWG-MRT).Leuk. Res. 2007; 31: 737-740https://doi.org/10.1016/j.leukres.2006.12.002
- A clinical-molecular prognostic model to predict survival in patients with post polycythemia vera and post essential thrombocythemia myelofibrosis.Leukemia. 2017; 31: 2726-2731https://doi.org/10.1038/leu.2017.169
- A dynamic prognostic model to predict survival in post-polycythemia vera myelofibrosis.Blood. 2008; 111: 3383-3387https://doi.org/10.1182/blood-2007-11-121434
- Survival and prognosis of patients with polycythemia vera: a study of 816 patients in a single Chinese center.Zhonghua Yi Xue Za Zhi. 2015; 95: 1364-1368
- Thrombosis among 1537 patients with JAK2(V617F) -mutated myeloproliferative neoplasms: risk factors and development of a predictive model.Cancer Med. 2020; 9: 2096-2105https://doi.org/10.1002/cam4.2886
- The 2016 revision to the World Health Organization classification of myeloid neoplasms and acute leukemia.Blood. 2016; 127 (Blood.128(3)(2016): 462-463): 2391-2405https://doi.org/10.1182/blood-2016-06-721662
- A systematic review and meta-analysis of the prevalence of thrombosis and bleeding at diagnosis of Philadelphia-negative myeloproliferative neoplasms.BMC Cancer. 2019; 19: 184https://doi.org/10.1186/s12885-019-5387-9
- Bleeding, thrombosis, and anticoagulation in myeloproliferative neoplasms (MPN): analysis from the German SAL-MPN-registry.J. Hematol. Oncol. 2016; 18 (9)https://doi.org/10.1186/s13045-016-0242-9
- The role of monocytes in angiogenesis and atherosclerosis.J. Am. Coll. Cardiol. 2014; 63: 1-11https://doi.org/10.1016/j.jacc.2013.09.019
- Hematologic variables and venous thrombosis: red cell distribution width and blood monocyte count are associated with an increased risk.Haematologica. 2014; 99: 194-200https://doi.org/10.3324/haematol.2013.083840
- Gas6 promotes inflammatory (CCR2(hi)CX3CR1(lo)) monocyte recruitment in venous thrombosis.Arterioscler. Thromb. Vasc. Biol. 2017; 37: 1315-1322https://doi.org/10.1161/atvbaha.116.308925
- The JAK2 V617F mutational status and allele burden may be related with the risk of venous thromboembolic events in patients with Philadelphia-negative myeloproliferative neoplasms.Thromb. Res. 2015; 135: 272-280https://doi.org/10.1016/j.thromres.2014.11.006
- Clonal hematopoiesis and risk of atherosclerotic cardiovascular disease.N. Engl. J. Med. 2017; 377: 111-121https://doi.org/10.1056/NEJMoa1701719
- Thrombotic risk detection in patients with polycythemia vera: the predictive role of DNMT3A/TET2/ASXL1 mutations.Cancers (Basel). 2020; 12https://doi.org/10.3390/cancers12040934
- Risk factors for recurrent thrombosis in patients with polycythemia vera and essential thrombocythemia.Zhonghua Xue Ye Xue Za Zhi. 2019; 40: 17-23https://doi.org/10.3760/cma.j.issn.0253-2727.2019.01.004